Hi Vassilis, Thanks for your input . It's good to know that there is still some usage that jaxb or xmlbeans can't nicely handle. I am curious to know more details about this use case about transfering Map Of Maps or Map of Collections. Could you please paste a test case or some code snippet to have a look ?
Thanks, Jim On Mon, Apr 29, 2024 at 5:46 PM Vassilis Virvilis <v.virvi...@biovista.com> wrote: > I am using it. > > Although I plan to move to JAX-RS. However, I can't be sure about the > scheduling... > > Aegis is the simplest and most versatile databinding for java first > development in my opinion. > > The others (jax-ws, jaxb and xmlbeans) never worked for me when I had to > transfer > Map Of Maps or Map of Collections. > > I just wanted to give you my one datapoint. I understand that the > developers will have to weigh > carrying around a databinding vs its existing usage vs the development > effort required. > > Vassilis > > On 4/22/24 6:06 AM, Jim Ma wrote: > > Hi all, > > I am not sure if it's the time to deprecate some old cxf things that no > one > > is using, so I write to get your thoughts/ideas here. > > The first I can think of is aegis databinding. Is the aegis databinding > > still used by CXF users ? Is it a good time to deprecate and remove in > the > > future release ? > > > > Thanks, > > Jim > > > > -- > > __________________________________ > > Vassilis Virvilis Ph.D. > Head of IT > Biovista Inc. > > Stay tuned > www: http://www.biovista.com > LinkedIn: https://www.linkedin.com/company/biovista > Twitter: https://twitter.com/BiovistaInc/ > Vizit https://twitter.com/BiovistaVizit/ > Facebook: https://www.facebook.com/biovistainc > Vizit (research): https://www.facebook.com/BiovistaVizit > YouTube: https://www.youtube.com/user/BiovistaInc > > -- > US Offices > 2421 Ivy Road > Charlottesville, VA 22903 > USA > T: +1.434.971.1141 > F: +1.434.971.1144 > > European Offices > 34 Rodopoleos Street > Ellinikon, Athens 16777 > GREECE > T: +30.210.9629848 > F: +30.210.9647606 > > Biovista is a privately held biotechnology company that finds novel uses > for existing drugs, and profiles their side effects using their mechanism > of action. Biovista develops its own pipeline of drugs in CNS, oncology, > auto-immune and rare diseases. Biovista is collaborating with > biopharmaceutical companies on indication expansion and de-risking of their > portfolios and with the FDA on adverse event prediction. > >
